HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Meningioma

Meningioma is a type of tumor that originates in the meninges, which are the layers of tissue covering the brain and spinal cord. These tumors are typically slow-growing and often benign, meaning they are non-cancerous. Meningiomas are more common in women than in men and are frequently diagnosed in individuals between the ages of 30 and 70. The exact cause of meningiomas is not well understood, but certain risk factors, such as exposure to radiation and hormonal changes, may contribute to their development. Most meningiomas do not cause noticeable symptoms, and their presence is often incidental, discovered during imaging tests for unrelated issues. In cases where symptoms do occur, they can vary widely depending on the tumor's size and location. Common symptoms may include headaches, seizures, changes in vision, and neurological deficits. Treatment options for meningiomas depend on factors like the tumor's size, location, and overall health of the patient. Small and asymptomatic meningiomas may be monitored regularly without immediate intervention. Radiation therapy and, in some cases, medications may also be considered as part of the treatment plan. Prognosis for meningiomas is generally favorable, especially for benign tumors that are completely removed. Regular follow-up and monitoring are essential to detect any potential recurrence. Overall, the management of meningiomas involves a collaborative approach between neurosurgeons, oncologists, and other healthcare professionals to tailor the treatment to the individual patient's needs.

Committee Members
Speaker at International Cancer Conference 2026 - Rajvir Dahiya

Rajvir Dahiya

University of California San Francisco, United States
Speaker at International Cancer Conference 2026 - Patricia Tai

Patricia Tai

UpToDate, Canada
Speaker at International Cancer Conference 2026 - Jose Manuel Cervera Grau

Jose Manuel Cervera Grau

Preclinical Lab and Computational Drug Discovery Program, Relayer Biotech Inc, Spain

Submit your abstract Today

Facebook Twitter XTwitter Youtube
Watsapp